›Teva Announces Agreement with Ranbaxy Regarding Generic Lipitor
30-Nov-2011 11:00pm ET
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited ("Ranbaxy"), a portion of the profits from Ranbaxy’s sales of Atorvastatin Calcium Tablets during Ranbaxy’s 180-day first-to-file exclusivity period, will be paid to Teva. Terms of the agreement will not be disclosed.‹